Results 1 to 10 of about 981,647 (48)

Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis

Clinical Infectious Diseases, 2022
Therapeutic drug monitoring (TDM) of beta-lactam antibiotics is recommended to address the variability in exposure observed in critical illness. However, the impact of TDM-guided dosing on clinical outcomes remains unknown.
R. P. Mangalore, Aadith Ashok, Sue J. Lee, L. Romero, T. Peel, A. Udy, A. Peleg   +6 more
semanticscholar   +1 more source

Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial

Intensive Care Medicine, 2022
Individualising drug dosing using model-informed precision dosing (MIPD) of beta-lactam antibiotics and ciprofloxacin has been proposed as an alternative to standard dosing to optimise antibiotic efficacy in critically ill patients.
T. Ewoldt, A. Abdulla, W. Rietdijk, A. Muller, B. D. de Winter, N. Hunfeld, I. Purmer, P. van Vliet, E. Wils, J. Haringman, A. Draisma, T. Rijpstra, A. Karakus, D. Gommers, H. Endeman, B. Koch   +15 more
semanticscholar   +1 more source

Cephalosporins as key lead generation beta-lactam antibiotics

Applied Microbiology and Biotechnology, 2022
Antibiotics are antibacterial compounds that interfere with bacterial growth, without harming the infected eukaryotic host. Among the clinical agents, beta-lactams play a major role in treating infected humans and animals.
Xuemei Lin, U. Kück
semanticscholar   +1 more source

Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?

Critical Care Explorations, 2021
Supplemental Digital Content is available in the text. OBJECTIVES: Beta-lactam antibiotics exhibit high interindividual variability in drug concentrations in patients with critical illness which led to an interest in the use of therapeutic drug ...
E. Barreto, Andrew J. Webb, Gwendolyn M. Pais, A. Rule, P. Jannetto, M. Scheetz   +5 more
semanticscholar   +1 more source

Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)

Critical Care, 2020
Background Early and appropriate antibiotic dosing is associated with improved clinical outcomes in critically ill patients, yet target attainment remains a challenge.
A. Abdulla, A. Dijkstra, N. Hunfeld, H. Endeman, S. Bahmany, T. Ewoldt, A. Muller, T. van Gelder, D. Gommers, B. Koch   +9 more
semanticscholar   +1 more source

The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial

BMC Infectious Diseases, 2020
Background Critically ill patients undergo extensive physiological alterations that will have impact on antibiotic pharmacokinetics. Up to 60% of intensive care unit (ICU) patients meet the pharmacodynamic targets of beta-lactam antibiotics, with only 30%
A. Abdulla, T. Ewoldt, N. Hunfeld, A. Muller, W. Rietdijk, S. Polinder, T. V. Gelder, H. Endeman, B. C. Koch   +8 more
semanticscholar   +1 more source

Practical guide for evaluation and management of beta-lactam allergy: position statement from the Canadian Society of Allergy and Clinical Immunology

Allergy, Asthma & Clinical Immunology, 2020
The vast majority of individuals labelled as allergic are not deemed truly allergic upon appropriate assessment by an allergist. A label of beta-lactam allergy carries important risks for individual and public health. This article provides an overview of
S. Jeimy, M. Ben-Shoshan, E. Abrams, A. Ellis, L. Connors, Tiffany Wong   +5 more
semanticscholar   +1 more source

Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor

Nature Communications, 2020
Beta-lactamase inhibitors are increasingly used to counteract antibiotic resistance mediated by beta-lactamase enzymes. These inhibitors compete with the beta-lactam antibiotic for the same binding site on the beta-lactamase, thus generating an ...
Dor Russ, F. Glaser, Einat Shaer Tamar, I. Yelin, M. Baym, Eric D. Kelsic, C. Zampaloni, A. Haldimann, R. Kishony   +8 more
semanticscholar   +1 more source

Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’

Critical Care, 2019
BackgroundBeta-lactam antibiotics (βLA) are the most commonly used antibiotics in the intensive care unit (ICU). ICU patients present many pathophysiological features that cause pharmacokinetic (PK) and pharmacodynamic (PD) specificities, leading to the ...
R. Guilhaumou, S. Benaboud, Y. Bennis, C. Dahyot-Fizelier, E. Dailly, P. Gandia, S. Goutelle, S. Lefeuvre, N. Mongardon, C. Roger, J. Scala-Bertola, F. Lemaitre, M. Garnier   +12 more
semanticscholar   +1 more source

Pharmacokinetics–pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients

Critical Care, 2018
Antimicrobials are among the most important and commonly prescribed drugs in the management of critically ill patients and beta-lactams are the most common antibiotic class used.
R. Veiga, J. Paiva
semanticscholar   +1 more source